It has been observed that co-administration of aromatase inhibitor and microtubule-modulating drugs can improve clinical effectiveness in breast cancer patients.11,12 Despite of these positive outcomes, such combinations can increase the risk of adverse effects, drug interactions, and detrimental physiological change. Here, CYP19A1 is linked to breast cancer.